Table 1.

Surfactants described in the Investigational Medicinal Product Dossiers (IMPDs).

Surfactant	Function	Study Phases	Therapeutic Areas (Number of Instances)	% of Use
Lauroyl polyoxyl-32 glycerides (Gelucire 44/14)	Surfactant	II	Physiological processes (1)	0.49
Mannide monooleate	Emulsifier	I	Cancer (1)	0.49
Sodium lauryl sulfate	Surfactant	III	Blood and lymphatic diseases (1) Cancer (9) Immune system diseases (1) Musculoskeletal diseases (2) Nervous system diseases (1)	6.86
Polyoxyl 40 hydrogenated castor oil	Surfactant	III	Blood and lymphatic diseases (2) Cancer (1) Immune system diseases (1)	1.96
Poloxamer 188 (Pluronic F-68)	Surfactant	I/II/III	Blood and lymphatic diseases (2) Cancer (1) Eye diseases (2) Immune system diseases (3) Nervous system diseases (2) Nutritional and metabolic diseases (1) Respiratory tract diseases (1)	5.88
Poloxamer 407	Surfactant Plasticizer	I/II	Cancer (1) Nervous system diseases (1)	0.98
Polysorbate 20 (Tween 20)	Surfactant Stabilizing agent	I/II/III	Bacterial infections and mycoses (1) Blood and lymphatic diseases (1) Cancer (45) Cardiovascular diseases (3) Digestive system diseases (4) Eye diseases (6) Immune system diseases (5) Nervous system diseases (5) Nutritional and metabolic diseases (1) Virus diseases (4)	36.76
Polysorbate 80 (Tween 80)	Surfactant Stabilizing agent	I/II/III	Digestive system and oral physiological phenomena (2) Metabolic phenomena (1) Blood and lymphatic diseases (5) Cancer (57) Cardiovascular diseases (2) Congenital, hereditary and neonatal diseases and abnormalities (1) Digestive system diseases (5) Eye diseases (1) Immune system diseases (7) Nervous system diseases (8) Nutritional and metabolic diseases (1) Respiratory tract diseases (1) Skin and connective tissue diseases (3)	46.08
Propylene glycol monocaprylate, type I (Capryol PGMC)	Surfactant	II	Physiological processes (1)	0.49